Researchers at Cancer Treatment Centers of America® in Phoenix Evaluating Investigational Medication for HER2-Positive Breast Cancer, Now Enrolling Patients in Clinical Study

Researchers at Cancer Treatment Centers of America® in Phoenix Evaluating Investigational Medication for HER2-Positive Breast Cancer, Now Enrolling Patients in Clinical Study

Cancer Treatment Centers of America® (CTCA) in Phoenix is conducting a clinical trial of an investigational medication for HER2-positive (HER2+) breast cancer. The randomized pivotal study, called HER2CLIMB, is evaluating the investigational medication tucatinib in combination with approved standard treatments in patients with locally advanced or metastatic HER2-positive breast cancer, with or without brain metastases.

“Patients who have been diagnosed with HER2-positive breast cancer and whose cancer has spread to other parts of their body may benefit from treatment with HER2-targeted therapies,” said Cynthia Lynch, MD, medical oncologist, Medical Director of the Breast Center at CTCA® in Phoenix. “This investigational medication is designed to inhibit the activity of HER2 and is being evaluated in combination with other approved therapies. In addition, it is important to note that HER2CLIMB is enrolling patients with HER2-positive breast cancer that has spread to the brain, a patient population that is often excluded from clinical trials.”

Tucatinib is a HER2 inhibitor designed specifically to target and inhibit the growth of HER2-positive cancer cells. Tucatinib is an oral medication that can be taken at home.

To be eligible for the study, women or men must have locally advanced or metastatic HER2-positive breast cancer, with or without brain metastases, and meet certain other eligibility criteria. To learn more about this trial, visit cancercenter.com/clinical-trials or HER2CLIMB.com.